Since the advent of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has been transformed from a disease that was usually fatal into one in which patients have a close-to-normal life expectancy. In some cases, the response to treatment is sufficiently prolonged and deep that patients may be able to discontinue their medication. Is this a good idea? In this month's Counterpoints, Drs Nicholas Short and Elias Jabbour argue for the continued treatment of CML, whereas Drs Gabriel Etienne and François-Xavier Mahon make the case for treatment discontinuation.
http://www.hematolog...e-indefinitely/

Counterpoints: Should Treatment for CML Continue Indefinitely?
Started by
gerry
, Jun 26 2017 05:08 PM
1 reply to this topic
#1
Posted 26 June 2017 - 05:08 PM
#2
Posted 26 June 2017 - 05:14 PM
ASCO - US perspective of TKI therapy discontinuation in CML patients
http://www.cmladvoca...in-cml-patients
http://www.cmladvoca...in-cml-patients
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users